News

BALTIC16: Resistance potential and QoL issues in mCRPC patients

There are small gains made in the hormone and chemo-treatment of metastatic castration-resistant prostate cancer (mCRPC) but experts caution that the increased use of these new agents may lead to new patterns of resistance. “With increasing use of novel...

Baltic16: Quality of life in prostate cancer patients

Issues in diagnosing and treating prostate cancer particularly in patients with resistant or metastatic disease were taken up in several sessions at the 3rd EAU Baltic Meeting with experts saying that although there are new and emerging options a careful selection...

EAU to boost collaboration with Baltic region

The 3rd EAU Baltic Meeting opened today in Tallinn with more than 300 registered participants  and experts from and outside the region examining a range of challenges and prospects in the diagnosis and treatment of prostate, bladder and kidney...
Full room Baltic16

Baltic16 widens regional collaboration

A wide-ranging Scientific Programme awaits participants of the 3rd EAU Baltic Regional Meeting (Baltic16) in the Estonian capital of Tallinn from May 27 to 28 with onc-urological malignancies, andrology, urolithiasis, male and female incontinence surgery and a course on...

Baltic16: Sharing insights and new perspectives

From urological malignancies such as prostate and bladder cancers to management strategies in stone disease, incontinence and andrology, the EAU Baltic Regional Meeting (Baltic16) promises to be one of the most compact and stimulating urology meetings in the region....